ABIVAX Société Anonyme (AAVXF PINK) stock market data APIs
$5.8443
0(0%)
as of April 17, 2025
ABIVAX Société Anonyme Financial Data Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults and Phase 2b clinical trial of obefazimod in patients with Crohn's disease. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
5.8443
Open
5.8443
High
5.8443
Low
5.8443
52 wk Range
5.81-15.15
Market Cap
379 M
Shares Outstanding
63 419 K
Revenue
10 792 K
Beta
1.559
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ABIVAX Société Anonyme data using free add-ons & libraries
Get ABIVAX Société Anonyme Fundamental Data
ABIVAX Société Anonyme Fundamental data includes:
- Net Revenue: 10 792 K
- EBITDA: -171 883 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ABIVAX Société Anonyme News
New
Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
PARIS, FRANCE / ACCESSWIRE / July 11, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune...
Abivax receives "Capital Market Transaction of the Year Award" at the European Mediscience Awards 2023
The award recognizes a significant capital market transaction in the biotech sector Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and ...
Abivax Stock Included in MSCI Indexes
As of June 1st, the Abivax stock is represented in the MSCI Indexes The MSCI Indexes reflect the evolution of the world's equity markets to support investors building effective portfolios based on ris...
Abivax Releases the Results of its June 5, 2023 Ordinary and Extraordinary General Meeting
Shareholders approved all proposed resolutions PARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on d...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
